
Keywords: Acute pancreatitis; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists; Incretin-based therapies; Pancreatic cancer; AERS; Adverse Event Reporting System; CI; confidence interval; DCSI; Diabetes Complication Severity Index; DM; d